Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efalizumab -Genentech/XOMA

Drug Profile

Efalizumab -Genentech/XOMA

Alternative Names: Anti-CD11a monoclonal antibody - Genentech/Xoma; HU 1124; Hu1124; Raptiva; Xanelim™

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Merck Serono; XOMA
  • Class Monoclonal antibodies
  • Mechanism of Action CD11a antigen antagonists; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Psoriasis
  • Discontinued Psoriatic arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Jun 2009 Withdrawn for Psoriasis in Canada (SC)
  • 08 Jun 2009 Withdrawn for Psoriasis in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top